MOLOGNI LUCA

Ruolo: 
Ricercatore a tempo determinato
Settore scientifico disciplinare: 
BIOLOGIA APPLICATA (BIO/13)
Telefono: 
0264488148
0264488059
Stanza: 
U08, Piano: P04, Stanza: 4043
Via Cadore, 48 - 20900 MONZA
U8, Piano: IV, Stanza: LABORATORIO 4.10
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • Crespiatico, I., Bossi, E., Brioschi, F., Piazza, R., Mologni, L., & Gambacorti‐passerini, C. (2019). An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. CLINICAL CASE REPORTS. Dettaglio
  • Menotti, M., Ambrogio, C., Cheong, T., Pighi, C., Mota, I., Cassel, S., et al. (2019). Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. NATURE MEDICINE, 25(1), 130-140. Dettaglio
  • Geeta, G., & Mologni, L. (2019). We shall overcome (drug resistance) some day. ONCOTARGET, 10(2), 84-85. Dettaglio
  • Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio
  • Redaelli, S., Ceccon, M., Zappa, M., Sharma, G., Mastini, C., Mauri, M., et al. (2018). Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. CANCER RESEARCH, 78(24), 6866-6880. Dettaglio